DoW Amyotrophic Lateral Sclerosis Research Program Therapeutic Idea Award
This grant funds innovative, high-risk research ideas focused on discovering new ALS drugs or therapies, emphasizing impact and approach over existing preliminary data.
Funder: Dept. of the Army -- USAMRAA
Due Dates: June 24, 2026: Pre-Application (Preproposal) | September 30, 2026: Full Application | October 6, 2026: End of Application Verification Period
Funding Amounts: Estimated total program funding: $10.08M; up to $840,000 total costs per award over 2 years; ~12 awards expected.
Summary: Supports innovative, high-risk/high-gain research for ALS drug or therapy discovery, emphasizing hypothesis-driven studies and impactful innovation.
Key Information: Pre-application is required; only invited applicants may submit a full application.
Description
This opportunity funds the development of bold, innovative, and high-risk/high-gain ideas for the discovery of new drugs or therapies for amyotrophic lateral sclerosis (ALS). The program seeks hypothesis-driven research that generates preliminary data to enable future therapeutic development. Projects may include investigational drug or device studies (but not clinical trials), and must incorporate rational biomarker development aligned with the therapeutic strategy. The award is designed to catalyze novel, transformative approaches with the potential for significant impact on ALS treatment, especially those that could lay the foundation for new directions in the field.
